[1]王兴纯,曲伸.胰高血糖素样肽-1受体激动剂与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2014,(01):40-42.[doi:10.3760/cma.j.issn.1673-4157.2014.01.011]
 Wang Xingchun*,Qu Shen.Glucagon like peptide-1 receptor agonist and nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(01):40-42.[doi:10.3760/cma.j.issn.1673-4157.2014.01.011]
点击复制

胰高血糖素样肽-1受体激动剂与非酒精性脂肪性肝病()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2014年01期
页码:
40-42
栏目:
综述
出版日期:
2014-02-28

文章信息/Info

Title:
Glucagon like peptide-1 receptor agonist and nonalcoholic fatty liver disease
作者:
王兴纯曲伸
210029 南京医科大学(王兴纯);200072 上海同济大学附属第十人民医院内分泌代谢科(曲伸)   
Author(s):
Wang Xingchun*Qu Shen.
*Nanjing Medical University,Nanjing 210029,China Corresponding author:Qu Shen,Email:qushencn@hotmail.com
关键词:
GLP-1受体激动剂肝功能脂肪含量非酒精性脂肪性肝病
Keywords:
GLP-1 receptor agonistLiver functionFat contentNonalcoholic fatty liver disease
DOI:
10.3760/cma.j.issn.1673-4157.2014.01.011
摘要:
胰高血糖素样肽-1(GLP-1)受体激动剂作为治疗糖尿病的新型药物得到广泛应用。近年来的研究显示,此类药物能够通过改善血脂水平、降低脂肪含量、减少肝脂肪变性、肝纤维化程度及细胞死亡等机制,实现降低转氨酶水平以改善非酒精性脂肪性肝病的作用。
Abstract:
As new antidiabetic drugs,glucagon-like peptide-1(GLP-1) receptor agonists have been widely used.Recent studies suggest that these drugs can reduce transaminase level to improve nonalcoholic fatty liver disease by improving blood lipid levels,decreasing the content of fat,reducing fatty degeneration of the liver,the degree of liver fibrosis and cell death.

参考文献/References:

[1] Lund A,Knop FK,Vilsb?觟ll T.Emerging GLP-1 receptor agonists[J].Expert Opin Emerg Drugs,2011,16(4):607-618.
[2] Vilsb?觟ll T,Christensen M,Junker AE,et al.Effects of glucagon-like peptide-1 receptor agonists on weight loss:systematic review and meta-analyses of randomised controlled trials[J].BMJ,2012,344:d7771.
[3] Ohki T,Isogawa A,Iwamoto M,et al.The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone[J].Sci World J,2012,2012:496453.
[4] Cuthbertson DJ,Irwin A,Gardner CJ,et al.Improved glycaemia correlates with liver fat reduction in obese,type 2 diabetes,patients given glucagon-like peptide-1 (GLP-1)receptor agonists[J].PLoS One,2012,7(12):e50117.
[5] Samson SL,Sathyanarayana P,Jogi M,et al.Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial[J].Diabetologia,2011,54(12):3093-3100.
[6] Sathyanarayana P,Jogi M,Muthupillai R,et al.Effects of com-bined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes[J].Obesity (Silver Spring),2011,19(12):2310-2315.
[7] Kelly AS,Bergenstal RM,Gonzalez-Campoy JM,et al.Effects of exenatide vs.metformin on endothelial function in obese patients with pre-diabetes:a randomized trial[J].Cardiovasc Diabetol,2012,11:64.
[8] Klonoff DC,Buse JB,Nielsen LL,et al.Exenatide effects on diabetes, obesity,cardiovascular risk factors and hepatic biomark-ers in patients with type 2 diabetes treated for at least 3 years[J].Curr Med Res Opin,2008,24(1):275-286.
[9] Drucker DJ,Buse JB,Taylor K,et al.Exenatide once weekly versus twice daily for the treatment of type 2 diabetes:a randomised,open-label,non-inferiority study[J].Lancet,2008,372(9645):1240-1250.
[10] Bello NT,Kemm MH,Ofeldt EM,et al.Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates[J].Am J Physiol Regul Integr Comp Physiol,2010,299(3):R945-R952.
[11] Jendle J,Nauck MA,Matthews DR,et al.Weight loss with liraglutide,a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue[J].Diabetes Obes Metab,2009,11(12):1163-1172.
[12] Inoue K,Maeda N,Kashine S,et al.Short-term effects of liraglutide on visceral fat adiposity,appetite,and food preference: a pilot study of obese Japanese patients with type 2 diabetes[J].Cardiovasc Diabetol,2011,10:109.
[13] Kelly AS,Rudser KD,Nathan BM,et al.The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity:a randomized,placebo-controlled, clinical trial[J].JAMA,2013,167(4):355-360.
[14] Hopkins ND,Cuthbertson DJ,Kemp GJ,et al.Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients[J].Diabetes Obes Metab,2013,15(8):770-773.
[15] Ding X,Saxena NK,Lin S,et al.Exendin-4,a glucagon-like protein-1(GLP-1)receptor agonist,reverses hepatic steatosis in ob/ob mice[J].Hepatology,2006,43(1):173-181.
[16] Vendrell J,El Bekay R,Peral B,et al.Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance[J].Endocrinology,2011,152(11):4072-4079.
[17] Gupta NA,Kolachala VL,Jiang R,et al.The glucagon-like peptide-1 receptor agonist exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis[J].AM J Pathol,2012,181(5):1693-1701.
[18] Gupta NA,Mells J,Dunham RM,et al.Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway[J].Hepatology,2010,51(5):1584-1592.
[19] Trevaskis JL,Griffin PS,Wittmer C,et al.Glucagon-like pep-tide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice[J].Am J Physiol Gastrointest Liver Physiol,2012,302(8):G762-G772.
[20] Sharma S,Mells JE,Fu PP,et al.GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy[J]. PLoS One,2011,6(9):e25269.
[21] Ben-Shlomo S,Zvibel I,Shnell M,et al.Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase[J].J Hepatol,2011,54(6):1214-1223.
[22] Dushay J,Chui PC,Gopalakrishnan GS,et al.Increased fibrob-last growth factor 21 in obesity and nonalcoholic fatty liver disease[J].Gastroenterology,2010,139(2):456-463.
[23] Cnop M,Ladrière L,Igoillo-Esteve M,et al.Causes and cures for endoplasmic reticulum stress in lipotoxic beta-cell dysfunction[J].Diabetes Obes Metab,2010,12 (Suppl 2):76-82.
[24] 张学力,郗光霞,赵媛媛,等.艾塞那肽对糖耐量减低大鼠肝脏内质网应激标志性蛋白C/EBP同源蛋白表达的作用[J].中国药物与临床,2012,2:167-169.
[25] Vanni E,Bugianesi E,Kotronen A,et al. From the metabolic syndrome to NAFLD or vice versa[J]?.Dig Liver Dis,2010,42(5):320-330.

相似文献/References:

[1]王兴纯,曲伸.GLP-1及其受体激动剂与炎性反应及氧化应激[J].国际内分泌代谢杂志,2014,(04):263.[doi:10.3760/cma.j.issn.1673-4157.2014.04.014]
 Wang Xingchun,Qu Shen..Association of GLP-1 and its receptor agonist with inflammation and oxidative stress[J].International Journal of Endocrinology and Metabolism,2014,(01):263.[doi:10.3760/cma.j.issn.1673-4157.2014.04.014]

备注/Memo

备注/Memo:
基金项目:2012年中华医学会临床医学科研专项基金(120120 550355);2012年上海市卫生局申康慢病综合防治项目(SHDC120 12303) 通信作者:曲伸,Email:qushencn@hotmail.com
更新日期/Last Update: 2014-01-20